Perspective Therapeutics (CATX) Other Non-Current Assets (2011 - 2026)
Perspective Therapeutics' (CATX) quarterly Other Non-Current Assets came in at $490000.0 in Q1 2026, up 33.88% year-on-year from $366000.0 in Q1 2025, and up 0.82% quarter-over-quarter from $486000.0 in Q4 2025.
Perspective Therapeutics (CATX) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Other Non-Current Assets across 16 years of filings, most recently posting $490000.0 for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $490000.0, up 33.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $490000.0 (up 33.88% YoY), and the FY2025 annual result was $486000.0, up 20.0% from the prior year.
- Other Non-Current Assets came in at $490000.0 for Q1 2026 at Perspective Therapeutics, up from $486000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $490000.0 in Q1 2026 to a low of $182000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $182000.0 (2022), against an average of $267000.0.
- Across the five-year window, Other Non-Current Assets changed 0.0% in 2022 and jumped 122.53% in 2024, its largest moves.
- Perspective Therapeutics' Other Non-Current Assets stood at $182000.0 in 2022, then changed by 0.0% to $182000.0 in 2023, then surged by 122.53% to $405000.0 in 2024, then grew by 20.0% to $486000.0 in 2025, then climbed by 0.82% to $490000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $490000.0 (Q1 2026), $486000.0 (Q4 2025), and $438000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 4.04 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 828.89 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 285.90 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 2.25 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 211.40 Mn |
| 10 | Perspective Therapeutics | 308.74 Mn | 308.74 Mn | - | 490,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 490,000.00 |
| Dec 31, 2025 | 486,000.00 |
| Sep 30, 2025 | 438,000.00 |
| Mar 31, 2025 | 366,000.00 |
| Dec 31, 2024 | 405,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 182,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 182,000.00 |
| Mar 31, 2023 | 182,000.00 |
| Dec 31, 2022 | 182,000.00 |
| Sep 30, 2022 | 182,000.00 |
| Jun 30, 2022 | 182,000.00 |
| Mar 31, 2022 | 182,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 182,000.00 |
| Jun 30, 2021 | 130,000.00 |
| Mar 31, 2021 | 182,000.00 |
| Dec 31, 2020 | 182,000.00 |